Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rotavirus Vaccine Workshop May Address Intussusception Biomarker Data

Executive Summary

A potential rotavirus vaccine-related intussusception biomarker could be a topic at a September workshop organized by the Centers for Disease Control & Prevention's National Vaccine Program Office and the National Vaccine Advisory Committee.

You may also be interested in...

GSK Rotavirus Vaccine Phase III Safety Trials Will Enroll 50,000 Children

GlaxoSmithKline will evaluate the rotavirus vaccine Rotarix in 50,000 children in Phase III safety trials set to begin at the end of 2001, Biologicals President Jean Stephenne told a London analysts conference Feb. 22.

Rotavirus Vaccine Phase III Trials May Require 60,000 - 100,000 Patients

Rotavirus vaccine Phase III studies may require between 60,000 and 100,000 patients to address rare adverse event risks, Thomas Fleming, PhD, University of Washington, said during the Vaccines & Related Biological Products Advisory Committee meeting May 11.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts